Summit Therapeutics appoints Panmure Gordon as joint broker
The drug discovery and development company, Summit Therapeutics, reported on Thursday the appointment of a leading investment bank as joint-broker with immediate effect.
FTSE AIM All-Share
755.04
10:05 25/04/24
n/a
n/a
Pharmaceuticals & Biotechnology
22,680.01
10:05 25/04/24
3.57%
782.51
Summit Therapeutics
20.50p
16:55 21/02/20
0.00%
0.00p
The AIM-listed company revealed that Panmure Gordon would become the company's joint-broker alongside N+1 Singer, a leading investment bank dedicated to serving small and medium-sized companies in the UK.
Summit is a biopharmaceutical company specialising in the discovery, development and commercialisation of novel medicines.